Zinzani, P. L. Et Al. 2021. Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin on Symptoms Associated With Health-Related Quality of Life in Relapsed/Refractory Classical Hodgkin Lymphoma in the Randomized Phase 3 KEYNOTE-204 Study. 2021 Blood Meeting , (Adelaide, Australia).

Zinzani, P. L., Ramchandren, R., Santoro, A., Paszkiewicz-Kozik, E., Gasiorowski,, R., Johnson, N. A., ... Oliveira, J. S. R. d.(2021). Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin on Symptoms Associated With Health-Related Quality of Life in Relapsed/Refractory Classical Hodgkin Lymphoma in the Randomized Phase 3 KEYNOTE-204 Study . 2021 Blood Meeting, Adelaide, Australia

Zinzani, Pier Et Al. "Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin on Symptoms Associated With Health-Related Quality of Life in Relapsed/Refractory Classical Hodgkin Lymphoma in the Randomized Phase 3 KEYNOTE-204 Study," 2021 Blood Meeting, Adelaide, Australia, 2021

Zinzani, Pier L. Et Al. "Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin on Symptoms Associated With Health-Related Quality of Life in Relapsed/Refractory Classical Hodgkin Lymphoma in the Randomized Phase 3 KEYNOTE-204 Study." 2021 Blood Meeting , Adelaide, Australia, 2021

Zinzani, P. L. Et Al. (2021) . "Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin on Symptoms Associated With Health-Related Quality of Life in Relapsed/Refractory Classical Hodgkin Lymphoma in the Randomized Phase 3 KEYNOTE-204 Study." 2021 Blood Meeting , Adelaide, Australia.

@conferencepaper{conferencepaper, author={Pier Luigi Zinzani Et Al. }, title={Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin on Symptoms Associated With Health-Related Quality of Life in Relapsed/Refractory Classical Hodgkin Lymphoma in the Randomized Phase 3 KEYNOTE-204 Study}, congress name={2021 Blood Meeting}, city={Adelaide}, country={Australia}, year={2021}}